FIRST AMENDMENT TO DEVELOPMENT COLLABORATION AND EXCLUSIVE LICENSE AGREEMENTAnd Exclusive License Agreement • November 12th, 2019 • Molecular Templates, Inc. • Pharmaceutical preparations
This First Amendment to Development Collaboration and Exclusive License Agreement (this “Amendment”) is made and entered into as of July 18, 2019 (the “Amendment Effective Date”) by and between Molecular Templates, Inc., a Delaware corporation, having its principal place of business at 9301 Amberglen Boulevard, Suite 100, Austin, TX 78729 (“MTEM”), and Millennium Pharmaceuticals, Inc., a Delaware corporation and a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, having its principal place of business at 40 Landsdowne Street, Cambridge, MA 02139 (“Takeda”). MTEM and Takeda may be referred to herein collectively as the “Parties” and individually as a “Party.”
